A medical team described the experience of two patients who had both chronic lymphocytic leukemia (CLL), a type of blood cancer, and a related kidney problem called nephrotic syndrome. Nephrotic syndrome causes the kidneys to leak large amounts of protein into the urine, which can lead to swelling and other health issues. The doctors treated these patients with a combination of two targeted cancer drugs: obinutuzumab and venetoclax.
In both patients, the treatment was followed by a resolution of their nephrotic syndrome symptoms and a significant reduction in protein in their urine. For one patient, the improvement happened within weeks, and they remained in remission from both the kidney issue and their CLL at their last check-up. The report did not mention any specific side effects or safety problems from the treatment in these two individuals.
It is very important to understand that this is a case report involving only two people. There was no comparison group, and the condition itself is rare. This means we cannot say the treatment caused the improvement or that it would work for anyone else. The results are a promising observation that may guide future research, but they are not proof of effectiveness.
Readers should see this as an early, hopeful note from doctors about a potential treatment approach for a complex and rare complication of CLL. It highlights that kidney problems can occur with this cancer and may sometimes improve when the cancer is treated. Patients with similar conditions should discuss all treatment options with their own healthcare team, as this report does not establish a new standard of care.